Related Experiment Video
Updated: Jan 20, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Suicidality in treatment resistant depression: perspective for ketamine use
Katarzyna Jakuszkowiak-Wojten1, Maria Gałuszko-Węgielnik, Alina Wilkowska
1Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Dębinki St. 7 build. 25, 80-952 Gdańsk, Poland, k.jakuszkowiak@gumed.edu.pl.
Abstract:
Suicidal ideations or attempts in patients with major depressive disorder (MDD) are emergent conditions that require immediate treatment. Numerous therapeutic interventions to reduce suicide risk in psychiatric disorders are effective in long-term suicide prevention, but there is necessity of sufficient, rapid pharmacological treatment of suicidal risk in MDD. Ketamine, an N-methyl-D-aspartate (NMDA) antagonist, has been reported to have rapid antidepressant effect. Depressive symptoms, anxiety, hopelessness, suicidal ideation had decreased within hours after ketamine infusion. Ketamine's rapid symptoms relief and reduction of suicide thoughts has aroused growing interests in psychiatric association.
Related Concept Videos
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Vagus Nerve Stimulation Therapy to Manage Treatment-Resistant Depression
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Amplification of a Suicide Plasmid in a Bacterial Host
Treatment Resistant Cancers
07:12Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
